SEL ICB Lambeth Community Denosumab Service

A Contract Addendum Notice
by NHS SOUTH EAST LONDON INTEGRATED CARE BOARD

Source: Find a Tender
Type: Contract (Services)
Duration: not specified
Value: ___

Sector: HEALTH
Published: 28 Apr 2026
Delivery: not specified
Deadline: n/a

Related Terms

Location

London

Geochart for 1 buyers and 0 suppliers

1 buyer

NHS South East London Integrated Care Board London

Description

Provision of a community-based shared care service for the administration and monitoring of denosumab 60mg/ml for osteoporosis. The service will support patients in Lambeth (or registered with a Lambeth GP) who have been identified by secondary care as clinically appropriate for treatment in the community. The Provider will deliver blood monitoring, prescribing support, and timely administration of injections in accordance with the South East London Shared Care Agreement, while clinical responsibility remains with secondary care.

Ammendments to Previous Notice

2. VI.3 Additional information

This is a Provider Selection Regime (PSR) intention to award notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Procurement Act 2023 do not apply to this award. The publication of this notice marks the start of the standstill period. Representations by providers must be made to decision makers by Tuesday 12th May 2026. This contract has not yet formally been awarded; this notice serves as an intention to award under the PSR. Written representations should be sent to: hub.psrrepresentation@nhs.net Award Decision makers: Andrew Eyres- Corporate Director, Integrated Health and Adult Social Care There was no conflict of interest identified in the decision-making process. Evaluation Criteria and Weighting Scoring from 0-4, with percentage allocation based on the importance of the criteria in the service requirement. Key criteria: Quality and Innovation: 20% Value for Money: 25% Integration, Collaboration and Service Sustainability: 20% Improving Access, Reducing Health Inequalities and Facilitating Choice: 25% Social Value: 10% The criteria were applied with their respective weightings as specified, with scoring against a number of sub-categories for each criterion. An assessment against current and future performance for these individual sub-categories was undertaken, resulting in a combined overall score out of 100%. The publication of this notice marks the start of the standstill period, commencing on Wednesday Thursday 30th April 2026 ending at 23:59 on Tuesday 12 May 2026. Representations by providers must be submitted by 23:59 on Tuesday 12 May 2026 to: hub.psrrepresentation@nhs.net and must be made to the decision makers within this period. The contract may be formally awarded on Wednesday 13 May 2026, provided no representations are received, or once any representations have been addressed. This contract has not yet formally been awarded; this notice serves as an intention to award under the Provider Selection Regime (PSR). No conflicts of interest were identified in the decision-making process. Decision Makers and Dates of Decision The decision to proceed with the intention to award was made by: Andrew Eyres- Corporate Director, Integrated Health and Adult Social Care Lambeth Together Planning and Finance Group - 23 March 2026 Lambeth Together Senior Management Team - 31 March 2026 Rationale for Selection of Current Provider The current provider has demonstrated sustained high-quality performance and value for money, including: Maintaining 100% performance across key service standards, including: -Provision of service to all appropriately referred patients -Contacting patients within 72 hours of referral from secondary care -Issuing patient reminder cards and information leaflets -Providing consistent feedback from service users and referring acute trusts -Reporting 0% near misses or incidents from both the provider and acute trust -Effective financial management, remaining within the agreed budget -Delivery in line with NICE TA204 (Denosumab for the prevention of osteoporotic fractures in postmenopausal women) -Alignment with the South East London Osteoporosis Pathway and the South East London Shared Care Agreement for Denosumab 60mg/ml -Supporting care closer to home and improved patient experience through community-based administration of treatment -Sustained achievement of ≥95% across key performance indicators, including: -Timely patient contact within 72 hours -Provision of patient information materials -Service user and referrer feedback mechanisms -Incident reporting compliance -Annual patient satisfaction feedback demonstrating good service experience

3. VI.4.3. Precise information on deadline(s) for review procedures

The publication of this notice marks the start of the standstill period, commencing on Wednesday Thursday 30th April 2026 ending at 23:59 on Tuesday 12 May 2026. Representations by providers must be submitted by 23:59 on Tuesday 12 May 2026 to: hub.psrrepresentation@nhs.net and must be made to the decision makers within this period. The contract may be formally awarded on Wednesday 13 May 2026, provided no representations are received, or once any representations have been addressed.